Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,816Revenue $M131Net Margin (%)-36.2Altman Z-Score6.1
Enterprise Value $M3,672EPS $-0.5Operating Margin %-105.8Piotroski F-Score3
P/E(ttm)--Beneish M-Score38.6Pre-tax Margin (%)-38.2Higher ROA y-yY
Price/Book8.110-y EBITDA Growth Rate %--Quick Ratio2.7Cash flow > EarningsY
Price/Sales27.65-y EBITDA Growth Rate %--Current Ratio2.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-7.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-10.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M110ROIC % (ttm)-45.0Gross Margin Increase y-yN

Gurus Latest Trades with XON

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
XONFirst Eagle Investment 2015-06-30 Add0.01%$37.33 - $50.71
$ 34.77-18%Add 5.37%872,604
XONT Boone Pickens 2015-03-31 Add0.9%$26.08 - $50.16
$ 34.77-8%Add 75.00%17,500
XONFirst Eagle Investment 2015-03-31 Add$26.08 - $50.16
$ 34.77-8%Add 4.84%828,104
XONT Boone Pickens 2014-12-31 Buy 0.53%$16.61 - $28.02
$ 34.7751%New holding10,000
XONDavid Einhorn 2014-12-31 Sold Out -0.05%$16.61 - $28.02
$ 34.7751%Sold Out0
XONDavid Einhorn 2014-09-30 Reduce-0.06%$17.86 - $26.59
$ 34.7763%Reduce 47.39%197,278
XONDavid Einhorn 2014-06-30 Reduce-0.39%$15.3 - $25.93
$ 34.7764%Reduce 72.81%375,000
XONFirst Eagle Investment 2014-06-30 Buy 0.04%$15.3 - $25.93
$ 34.7764%New holding661,564
XONDavid Einhorn 2014-03-31 Reduce-0.26%$22.5 - $36.82
$ 34.7721%Reduce 37.58%1,379,014
XONT Boone Pickens 2013-12-31 Sold Out -0.47%$17.65 - $25.5
$ 34.7765%Sold Out0
XONDavid Einhorn 2013-09-30 Buy 0.86%$21.36 - $29.7
$ 34.7744%New holding2,176,868
XONT Boone Pickens 2013-09-30 Buy 0.47%$21.36 - $29.7
$ 34.7744%New holding12,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XON is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

XON: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KIRK RANDAL JCEO, 10% Owner 2015-01-27Buy555,556$2727.22view
KIRK RANDAL JCEO, 10% Owner 2014-05-13Buy65,173$15.19126.14view
Lehr Donald P.Chief Legal Officer 2014-05-13Buy1,850$15.99114.82view
Reed Thomas D.Chief Science Officer 2014-05-13Buy640$15.6120.19view
Krishnan SumaSVP--Product Development 2014-05-09Buy20,900$14.21141.73view
Krishnan Krish SCOO 2014-05-09Buy20,900$14.21141.73view
Kasser Thomas R.SVP--Food Sector 2014-05-09Buy10,000$13.39156.53view
Huang KellySVP-Consumer Sector 2014-05-09Buy3,200$15.78117.68view
KIRK RANDAL JCEO, 10% Owner 2014-05-09Buy67,333$15.16126.58view
KIRK RANDAL JCEO, 10% Owner 2014-03-27Buy243,001$25.7233.55view

Quarterly/Annual Reports about XON:

    News about XON:

    Articles On GuruFocus.com
    Intrexon Corp is expanding his business Jun 25 2015 
    Bill Miller Identifies What Could Be The Stock of The Decade Feb 10 2015 
    5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
    Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
    Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
    David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
    Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

    More From Other Websites
    Fibrocell and Intrexon Announce Poster Presentation on FCX-007 for the Treatment of Recessive... Oct 08 2015
    Synthetic Biologics Initiates Second SYN-010 Phase 2 Clinical Trial Intended to Treat Irritable... Oct 08 2015
    Synthetic Biologics Initiates Second SYN-010 Phase 2 Clinical Trial Intended to Treat Irritable... Oct 08 2015
    Intrexon to Host Investor Day Oct 07 2015
    ALNY and XON Drag Down Mid-Cap Stocks Last Week Oct 02 2015
    Intrexon (XON) Falls: Stock Goes Down 5.4% Oct 02 2015
    Is Intrexon (XON) Stock a Solid Choice Right Now? Oct 01 2015
    Fibrocell to Present at 2015 Stem Cell Meeting on the Mesa Oct 01 2015
    Intrexon Establishes First Collaboration with Dedicated Fund Oct 01 2015
    The Approaching 'Vast Opportunity' For Intrexon Sep 30 2015
    INTREXON CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Sep 28 2015
    Intrexon and ZIOPHARM to Develop Immunotherapies for Treatment of Graft-Versus-Host Disease Sep 28 2015
    Three Biotech Stocks Are Down Today but Hedge Funds Say They Are Not Out Sep 28 2015
    XBI Mid-Caps Outperform IBB Mid-Caps Sep 28 2015
    Intrexon Strengthens Leadership Team Sep 28 2015
    ZIOPHARM Appoints Scott Tarriff to Its Board of Directors Sep 28 2015
    Synthetic Biologics Initiates SYN-004 Phase 2b Proof-of-Concept Clinical Trial Sep 28 2015
    Fibrocell and Intrexon Provide Regulatory Update for FCX-007 for the Treatment of Recessive... Sep 25 2015
    Kite Led Top Ten Stocks by Weight in XBI’s Biotechnology Subgroup Sep 24 2015
    Top Ten Stocks of XBI by Weight Outperform Sep 24 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)